BRIVA‐LIFE – a multicentre retrospective study of the long‐term use of brivaracetam in clinical practice

Abstract

Objectives

Evaluate long‐term effectiveness and tolerability of brivaracetam in clinical practice in patients with focal epilepsy.

Materials and Methods

This was a multicentre retrospective study. Patients aged ≥16 years were started on brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical records at 3, 6 and 12 months after treatment initiation for evaluation of safety‐ and seizure‐related outcomes.

Results

575 patients were included in analyses; most had been treated with ≥4 lifetime antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12 months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were ≥50% responders and 17.5% were seizure‐free. Seizure‐freedom was achieved by 37.5% of patients aged ≥65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) were 39.8% and 14.3%, respectively, and discontinuation due to these were 8.9% and 3.7%, respectively. Somnolence, irritability and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10–15). Among those who switched because of PAEs (n=52), 9 (17%) reported PAEs on brivaracetam, and 3 (3.7%) discontinued because of PAEs. Tolerability was not highly affected among patients with learning disability or psychiatric comorbidity.

Conclusions

In a large population of patients with predominantly drug‐resistant epilepsy, brivaracetam was effective and well‐tolerated; no unexpected AEs occurred over 1 year and the incidence of PAEs was lower compared with levetiracetam.

This article is protected by copyright. All rights reserved.

https://ift.tt/2QrATIS